At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Market Closed 01-16 16:00:00 EST
471.88
-4.48
-0.94%
High481.06Low464.47Vol18.36M
Open476.05D1 Closing476.36Amplitude3.48%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O205.37MT/O Rate--Tradable Shares0.00
P/B2.923491ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Not Just for Medical Inquiries: AI Healthcare Is Becoming the Next Golden Track
TradingKey  ·  01-16 21:46
Not Just for Medical Inquiries: AI Healthcare Is Becoming the Next Golden Track
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and DocGo (DCGO)
TIPRANKS  ·  01-15 19:10
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and DocGo (DCGO)
Edita Food Enters Into A Sale And Assignment Agreement With Hostess Brands
Reuters  ·  01-15 15:17
Edita Food Enters Into A Sale And Assignment Agreement With Hostess Brands
Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?
Simply Wall St.  ·  01-15 04:26
Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?
Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today
TIPRANKS  ·  01-14
Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today
Gene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring
Stock News  ·  01-13
Gene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?
Benzinga_recent_news  ·  01-13
Beam Therapeutics Stock Surges: What's Driving The Sudden Jump?
Beam Therapeutics Up Over 27%, on Track for Record Percent Increase -- Data Talk
Dow Jones  ·  01-13
Beam Therapeutics Up Over 27%, on Track for Record Percent Increase -- Data Talk
Beam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines
Dow Jones  ·  01-13
Beam Therapeutics Shares Climb After Updates to Treatment-Candidate Pipelines
Beam FDA alignment could accelerate review, says William Blair
TIPRANKS  ·  01-13
Beam FDA alignment could accelerate review, says William Blair
Beam Therapeutics higher after reaching FDA alignment on BEAM-302
TIPRANKS  ·  01-13
Beam Therapeutics higher after reaching FDA alignment on BEAM-302
Beam Therapeutics rises 23.4%
TIPRANKS  ·  01-12
Beam Therapeutics rises 23.4%
CRISPR Therapeutics Advances CTX310 and CTX320 Gene Editing Drugs in New Clinical Trials
Reuters  ·  01-12
CRISPR Therapeutics Advances CTX310 and CTX320 Gene Editing Drugs in New Clinical Trials
CRISPR Therapeutics AG Outlines 2026 Strategy with CASGEVY® Expansion, Advancement of Cardiovascular and Autoimmune Programs, siRNA Pipeline Growth, and Initiation of New Clinical Trials
Reuters  ·  01-12
CRISPR Therapeutics AG Outlines 2026 Strategy with CASGEVY® Expansion, Advancement of Cardiovascular and Autoimmune Programs, siRNA Pipeline Growth, and Initiation of New Clinical Trials
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
GlobeNewswire  ·  01-12
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics Ag : Bernstein Raises Target Price to $50 From $43
THOMSON REUTERS  ·  01-12
CRISPR Therapeutics Ag : Bernstein Raises Target Price to $50 From $43
Is Intellia Therapeutics (NTLA) Pricing Reflect Recent Share Rebound Or Long Term Challenges
Simply Wall St.  ·  01-12
Is Intellia Therapeutics (NTLA) Pricing Reflect Recent Share Rebound Or Long Term Challenges
BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises
Reuters  ·  01-12
BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises
Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs
Reuters  ·  01-12
Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs
Beam Therapeutics Projects Cash Runway Into 2029
Reuters  ·  01-12
Beam Therapeutics Projects Cash Runway Into 2029

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--